Jacob Witten (@JacobWitten1) header
Jacob Witten (@JacobWitten1) profile picture

Assistant Professor at Case Western Reserve University; gene therapy, lipid nanoparticles, lung disease

Joined July 2019
Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)Photo by Jacob Witten (@JacobWitten1)
Jacob Witten retweeted
I'm Trying to Cure My Cystic Fibrosis A personal essay by @JacobWitten1 about what it's like to live with cystic fibrosis and, at the same time, run a laboratory (and company) trying to cure it. Read: asimov.press/p/cystic-fibros…
2
5
25
2,482
Jacob Witten retweeted
A biologist in Ohio is living with a rare form of cystic fibrosis. His particular mutation is not amenable to existing drugs for the disease. And that’s why, for the last 10+ years, he has been trying to make a gene therapy to cure it. New essay today in @AsimovPress. Most people living with cystic fibrosis still make copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. These proteins are often defective, but modern drugs can help them fold or function properly. And these drugs have been enormously successful. For decades, treatments like antibiotics and mechanical vibration vests have helped clear bacteria from the airways and raise life expectancy for people with cystic fibrosis from about 10 years to 40. Newer drugs that restore CFTR function have pushed life expectancy even higher; many patients today can live relatively normal lives. But about 5–10% of people with cystic fibrosis have mutations that prevent them from making essentially any CFTR protein at all. These are often called nonsense or frameshift mutations. And because these patients don't make the protein, the existing CFTR-modulating drugs have nothing to act upon. @jacobwitten1, the author of today's essay, is one of these patients. His laboratory at Case Western Reserve University is developing lipid nanoparticles that can deliver RNA into lung cells, with the ultimate goal of restoring CFTR function. These particles could carry RNA strands encoding the missing protein, or gene-editing tools that fix the mutation directly. This is a deeply personal essay about the last 30 years of cystic fibrosis research, the extraordinary difficulty of delivering gene therapies into the lungs, and what it’s like to try to cure your own disease. We’re extremely honored that Jacob decided to write this! The piece is charming and irreverent and, I think, a reflection of his personality. press.asimov.com/articles/cy…
8
33
2
211
9,870
Jacob Witten retweeted
Most people have never heard of siRNA, but it’s going to change the face of medicine. worksinprogress.co/issue/the… Much drug development today involves developing chemicals to fit into proteins and block them. But this almost never turns out as planned: many drug candidates get broken down in the body, interfere with other proteins and cause toxic side effects, or fail to be absorbed at all. The majority of proteins are considered undruggable, because they lack a pocket for drugs to bind, or they are ‘intrinsically disordered’, without coherent structure. What if, instead of trying to block the protein, you could simply switch it off? In a new article, Jacob Witten explains the magic button to silence genes. siRNA, or ‘small interfering RNA’, is a short strand of RNA that blocks the production of proteins. As a brief refresher, proteins in the body are produced through the sequence: DNA --> mRNA --> protein. siRNA molecules bind to the intermediate mRNA and target it for destruction, meaning the protein isn’t produced. It’s a precision medicine: siRNA targets matching mRNA sequences like a barcode, so you can pick a gene of your choice, synthesize siRNA to match, deliver it to the right cells, and silence the protein. And a single dose can last months. Several siRNA drugs have already been developed: patisiran for hereditary transthyretin amyloidosis, inclisiran for high cholesterol, and fitusiran for hemophilia, are just a few examples. So far, all of them target the liver, which is an easy organ to deliver drugs to. But the principle can be applied to other organs too, and scientists are developing ‘molecular address labels’ to do it. And while some of these diseases are caused by a single gene, not all are. High cholesterol, for example, is a complex disease, but it can be targeted with siRNA drugs as well, because the disease’s pathway hinges on a critical protein, PCSK9. siRNA is exciting because it makes it possible to circumvent the problem of otherwise ‘undruggable’ proteins. And, unlike current gene-editing therapies, it can be given to people off the shelf, without needing to extract cells from the body, edit and replace them. But it’s still going to depend on having the right hypotheses of which genes to target and delivering the drugs safely to the right organs. We now have a kill switch for harmful genes. Read the full article here: worksinprogress.co/issue/the…
19
107
22
512
151,234
Jacob Witten retweeted
There is literally nothing that will prepare you for the future more than reading analytic philosophy
25
50
7
1,093
58,672
Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy go.nature.com/4fbj0VU
3
29
5
166
22,032
Deep learning regression model for antimicrobial peptide design biorxiv.org/cgi/content/shor… #biorxiv_bioinfo
3
8